PHOENIX, Oct. 06, 2017 (GLOBE NEWSWIRE) — Insys Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the Company”) today released the following statement: We would like to reiterate that we continue to work with relevant authorities to resolve issues related to inappropriate actions taken by some of our former employees. Accordingly, we have taken a series of major actions to prevent the mistakes of the past from happening in the future. With respect to the complaint filed by the New Jersey Attorney General this week, SUBSYS® (fentanyl sublingual spray) represented about 0.02 percent of the opioid prescriptions written in the United States in […]